Xbrane's year-end report showed lower revenue, consisting almost exclusively of delieveries to STADA leading to a higher loss on the EBIT level than we had projected. Redeye will downwards revise estimates and foresee an adverse reaction in the stock once the market opens.
LÄS MER
